• Molecular NameTizanidine
  • SynonymTizanidina [INN-Spanish]; Tizanidine Hcl; Tizanidinum [INN-Latin]
  • Weight253.717
  • Drugbank_IDDB00697
  • ACS_NO51322-75-9
  • Show 2D model
  • LogP (experiment)N/A
  • LogP (predicted, AB/LogP v2.0)1.68
  • pkaN/A
  • LogD (pH=7, predicted)-1.34
  • Solubility (experiment)N/A
  • LogS (predicted, ACD/Labs)(ph=7)-2.32
  • LogSw (predicted, AB/LogsW2.0)1.67
  • Sw (mg/ml) (predicted, ACD/Labs)0.31
  • No.of HBond Donors2
  • No.of HBond Acceptors5
  • No.of Rotatable Bonds2
  • TPSA90.44
  • StatusFDA approved
  • AdministrationOral, Intranasal, Injection
  • PharmacologyA drug that is used as a muscle relaxant.
  • Absorption_valueN/A
  • Absorption (description)N/A
  • Caco_2N/A
  • Bioavailability35.5
  • Protein binding30.0
  • Volume of distribution (VD)2.4 L/kg
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmTitanizine extensively metabolized in liver by CYP1A2 only, mainly through dihydroimidazol and benzothiadiazol rings hydroxylation.
  • Half life2.1~4.2 h
  • ExcretionN/A
  • Urinary ExcretionN/A
  • CleranceN/A
  • ToxicityN/A
  • LD50 (rat)N/A
  • LD50 (mouse)N/A